# Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder.

> **NCT02163915** · PHASE1 · TERMINATED · sponsor: **Takeda** · enrollment: 47 (actual)

## Conditions studied

- Attention-Deficit/Hyperactivity Disorder

## Interventions

- **DRUG:** TAK-137
- **DRUG:** TAK-137 Placebo

## Key facts

- **NCT ID:** NCT02163915
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-06
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 47 (ACTUAL)
- **Why stopped:** To allow evaluation of emerging non-clinical data (see detailed description below)
- **Last updated:** 2016-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02163915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02163915, "Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02163915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*